Company intelligence / Profile preview
PsychoGenics
Paramus, NJ, USApsychogenics.com ↗
- Ownership
- Private
- Employees
- ~120
- Development stage
- Preclinical
01
Overview
PsychoGenics has pioneered AI-driven phenotypic screening for neuropsychiatric drug discovery. Its SmartCube platform has led to the identification of several novel compounds now in clinical development with partners such as Sunovion and Roche. Notably, SEP‑363856 (“ulotaront”) is in Phase 3 trials for schizophrenia. The company also maintains an internal pipeline targeting agitation and treatment-resistant depression entering IND-enabling studies
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on PsychoGenics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PsychoGenics.